Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,492 across all filing types
Latest filing 2025-03-07 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
关于2025年2月份生猪销售简报
Regulatory Filings Classification · 95% confidence The document is a sales brief for February 2025 from Tian Kang Biological Co., Ltd., detailing monthly and cumulative sales volumes and revenues of live pigs. It includes comparative data with previous months and years, explanations for sales changes, and risk warnings. The document is short (1795 characters), contains no comprehensive financial statements or detailed financial analysis, and explicitly states that the data is unaudited and for reference only. It is a periodic sales update rather than a full financial report or earnings release. It does not fit the definitions of Annual Report, Interim Report, Earnings Release, or other detailed financial filings. It is an operational sales summary announcement. Given the nature and length, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-03-07 Chinese
关于变更部分募投项目实施地点和实施主体的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Tian Kang Biological Co., Ltd. regarding changes to the implementation location and implementing entity of certain projects funded by proceeds from a non-public stock issuance. It details the background of the fundraising, the specific changes to project locations and entities, reasons for the changes, and confirms that the changes do not affect the use of the funds or require shareholder approval. The document includes references to regulatory approvals, board and supervisory committee meetings, and opinions from the sponsoring institution. It is a formal disclosure about changes related to capital raised through financing activities, specifically the use of proceeds from a non-public stock issuance. There are no financial statements or comprehensive financial data presented, nor is it a full annual or interim report. It is not a call transcript, earnings release, or governance report. The content fits best under the category of Capital/Financing Update (CAP), as it updates investors and the market on changes related to the use of raised capital and project implementation funded by that capital.
2025-03-06 Chinese
关于开展商品期货套期保值业务的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Tian Kang Biological Co., Ltd. regarding the commencement of commodity futures hedging business. It details the purpose, scope, risk analysis, internal controls, and approvals related to the hedging activities. The document includes references to board and supervisory meetings approving the proposal and mentions that the matter will be submitted to the shareholders' meeting for approval. The text is an announcement of a business activity and related corporate governance steps, not a financial report, earnings release, or regulatory certification. It is not a report publication announcement since it contains substantive information about the business activity and risk controls. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a new business activity and risk disclosure, which does not fit other more specific categories like capital update or management change.
2025-03-06 Chinese
关于召开2025年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2025 first extraordinary general meeting (临时股东大会) of Tian Kang Biological Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), agenda items to be voted on, registration details, and proxy authorization forms. There is no financial data, earnings information, or management discussion of results. The document is not a report itself but an announcement and notice for a shareholder meeting. It does not contain voting results or changes in management but is a formal meeting notice. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or for the Annual or Extraordinary General Meeting, including meeting notices and agendas.
2025-03-06 Chinese
关于开展商品期货套期保值业务的可行性分析报告
Regulatory Filings Classification · 95% confidence The document is a detailed feasibility analysis report regarding the company's plan to conduct commodity futures hedging business. It discusses the purpose, scope, risk analysis, and control measures related to the futures hedging activities. The document is issued by the company's board and dated March 7, 2025. It is not a financial report like an annual or interim report, nor is it an announcement of voting results or a regulatory filing. It is a standalone report analyzing a specific business activity (commodity futures hedging) and its feasibility, risks, and controls. This type of document fits best under the category of Regulatory Filings (RNS) as it is a regulatory disclosure about a business activity and risk management, but does not fit into other more specific categories such as capital updates or management changes.
2025-03-06 Chinese
中信建投证券股份有限公司关于天康生物股份有限公司终止部分募投项目并将募集资金永久补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (中信建投证券股份有限公司) regarding the termination of part of a fundraising investment project by 天康生物股份有限公司 and the permanent supplementation of the raised funds into working capital. It includes specifics about the non-public stock issuance, fundraising amounts, project investment details, reasons for termination, and approvals by the board and supervisory committee. The document is a formal verification and opinion report related to fundraising and capital use, not a financial report like an annual or interim report. It is not a simple announcement but a detailed verification opinion on a capital/financing update matter. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is under 5,000 characters but contains substantive content and detailed financial and procedural information, so it is not a mere announcement (RPA) or regulatory filing (RNS).
2025-03-06 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.